When injecting over bony areas, HA products and calcium hydroxylapatite are acceptable, because the defects are generally smaller and there is less surface area on which to see ripples.
Dr. Rubin is a consultant for Medicis. He also has been involved in FDA clinical trials for Restylane, Perlane, and Artefill. SDEF and this news organization are owned by Elsevier.